Interconversion of tetrahydrofolate cofactors to dihydrofolate induced by trimetrexate after suppression of thymidylate synthase by fluorodeoxyuridine in L1210 leukemia cells.
Previous studies from this laboratory demonstrated that marked suppression of thymidylate synthase activity is required to slow the rate of interconversion of tetrahydrofolate cofactors to dihydrofolate when dihydrofolate reductase is blocked by an antifolate. This finding is due to the high catalytic activity of thymidylate synthase within cells in comparison to the tetrahydrofolate cofactor pool size. In the present study, we assessed the rate of resumption of thymidylate synthase catalytic activity in terms of [3H]deoxyuridine incorporation into DNA and dihydrofolate generation from tetrahydrofolate cofactors following exposure of cells to fluorodeoxyuridine. Log phase L1210 leukemia cells, incubated with fluorodeoxyuridine to abolish thymidylate synthase catalytic activity, were suspended into drug-free medium. Resumption of [3H]deoxyuridine incorporation into DNA was negligible; by 4 hr enzyme activity was still inhibited by approximately 98%. However, this was sufficient to interconvert all available tetrahydrofolate cofactors to dihydrofolate (T1/2 approximately 2 hr) when dihydrofolate reductase was inhibited by the lipophilic antifolate trimetrexate. Interconversion of tetrahydrofolate cofactors to dihydrofolate correlated with a decline, then cessation, of purine synthesis as measured by the incorporation of [14C]formate into purine bases. These data suggest that an earlier than previously expected depletion of tetrahydrofolate cofactors with consequent inhibition of purine and other folate-dependent synthetic processes is likely to occur when antifolates are administered after a fluoropyrimidine.
Seither
R L
RL
Department of Medicine, Virginia Commonwealth University, Medical College of Virginia, Richmond 23298.
Rape
T J
TJ
Goldman
I D
ID
D000818:Animals; D003198:Computer Simulation; D004247:DNA / Q000378:metabolism; D003857:Deoxyuridine / Q000378:metabolism; D004793:Enzyme Reactivators / Q000494:pharmacology*; D005467:Floxuridine / Q000494:pharmacology*; D005492:Folic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D005493:Folic Acid Antagonists; D002955:Leucovorin / Q000494:pharmacology; D007939:Leukemia L1210; D051379:Mice; D011687:Purines / Q000378:metabolism; D013763:Tetrahydrofolates / Q000378:metabolism; D013816:Thermodynamics; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors*; D013997:Time Factors; D016597:Trimetrexate / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D004793:Enzyme Reactivators; D005493:Folic Acid Antagonists; D011687:Purines; D013763:Tetrahydrofolates; D005467:Floxuridine; C010920:dihydrofolate; C030371:5,6,7,8-tetrahydrofolic acid; D004247:DNA; D005492:Folic Acid; D013940:Thymidylate Synthase; D002955:Leucovorin; D016597:Trimetrexate; D003857:Deoxyuridine